Medtronic Affera Mapping And Ablation System With Sphere-9 Catheter Achieves Endpoints For Safety And Efficacy
Portfolio Pulse from Benzinga Newsdesk
Medtronic's Affera Mapping and Ablation System with Sphere-9 Catheter has achieved positive safety and efficacy endpoints. The Sphere-9 Catheter demonstrated a low primary safety endpoint rate of 1.4%, with no significant safety events reported. It also showed superior efficiency and effectiveness in treating atrial fibrillation compared to the control arm.
May 17, 2024 | 8:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Medtronic's Sphere-9 Catheter has demonstrated positive safety and efficacy results, which could boost investor confidence and potentially lead to a short-term increase in stock price.
The positive safety and efficacy results of the Sphere-9 Catheter are likely to enhance Medtronic's reputation in the medical device market. This could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100